Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 23567-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- SMTN antibody
- Antibody type
- Polyclonal
- Description
- SMTN antibody (Cat. #23567-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Coordination between cytoskeletal organization, cell contraction and extracellular matrix development, is depended on LOX for aneurysm prevention.
Glycosylation-Engineered Platelet Membrane-Coated Interleukin 10 Nanoparticles for Targeted Inhibition of Vascular Restenosis.
Vav2 promotes ductus arteriosus anatomic closure via the remodeling of smooth muscle cells by Rac1 activation.
Doxorubicin induces detrusor smooth muscle impairments through myosin dysregulation, leading to a risk of lower urinary tract dysfunction.
Aviram R, Zaffryar-Eilot S, Kaganovsky A, Odeh A, Melamed S, Militsin R, Pinnock CB, Shemesh A, Palty R, Ganesh SK, Hasson P
bioRxiv : the preprint server for biology 2024 Feb 29;
bioRxiv : the preprint server for biology 2024 Feb 29;
Glycosylation-Engineered Platelet Membrane-Coated Interleukin 10 Nanoparticles for Targeted Inhibition of Vascular Restenosis.
Li F, Rong Z, Chen T, Wang P, Di X, Ni L, Liu C
International journal of nanomedicine 2023;18:5011-5030
International journal of nanomedicine 2023;18:5011-5030
Vav2 promotes ductus arteriosus anatomic closure via the remodeling of smooth muscle cells by Rac1 activation.
Chen Y, Wu Y, Feng W, Luo X, Xiao B, Ding X, Gu Y, Lu Y, Yu Y
Journal of molecular medicine (Berlin, Germany) 2023 Dec;101(12):1567-1585
Journal of molecular medicine (Berlin, Germany) 2023 Dec;101(12):1567-1585
Doxorubicin induces detrusor smooth muscle impairments through myosin dysregulation, leading to a risk of lower urinary tract dysfunction.
Iguchi N, Dönmez Mİ, Carrasco A Jr, Wilcox DT, Pineda RH, Malykhina AP, Cost NG
American journal of physiology. Renal physiology 2019 Jul 1;317(1):F197-F206
American journal of physiology. Renal physiology 2019 Jul 1;317(1):F197-F206
No comments: Submit comment
No validations: Submit validation data